Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

HRQOL Analysis Further Supports Pembrolizumab/Lenvatinib for Frontline RCC

June 7th 2021

Frontline treatment with the combination of lenvatinib plus pembrolizumab in patients with metastatic renal cell carcinoma led to similar health-related quality of life outcomes and disease-related symptom scores vs sunitinib.

Dr. Choueiri on the Efficacy of Post-Nephrectomy, Adjuvant Pembrolizumab in RCC

June 4th 2021

Toni K. Choueiri, MD, discusses the efficacy of pembrolizumab as a post-nephrectomy adjuvant therapy for patients with renal cell carcinoma from the phase 3 KEYNOTE-564 trial.

Tivozanib Doubles DOR Vs Sorafenib in mRCC

June 4th 2021

Tivozanib led to a more than doubled median duration of response compared with sorafenib in patients with metastatic renal cell carcinoma.

Frontline Avelumab Maintenance Improves OS Regardless of Primary Tumor Site, Advanced Disease Type in Advanced Urothelial Cancer

June 4th 2021

Avelumab as frontline maintenance plus best supportive care demonstrated a survival benefit compared with BSC alone across several previously unreported subgroups of patients with advanced urothelial cancer who have progressed on first-line platinum-containing chemotherapy.

Extended Treatment With Darolutamide Well Tolerated, Prolongs Survival in Nonmetastatic CRPC

June 4th 2021

Darolutamide remained well tolerated with a highly favorable safety profile when combined with androgen deprivation therapy in the treatment of patients with nonmetastatic castration-resistant prostate cancer.

Adjuvant Pembrolizumab Significantly Improves DFS in Renal Cell Carcinoma

June 3rd 2021

Pembrolizumab was associated with a 32% reduction in the risk of disease recurrence or death compared with placebo as an adjuvant treatment for patients with clear cell renal cell carcinoma.

FDA Approval Insights: Tivozanib in Relapsed/Refractory Advanced RCC

June 3rd 2021

Dr. Rini discusses unique elements of the TIVO-3 trial, the significance of the FDA approval of tivozanib in advanced RCC, and potential next steps for research with the TKI in the paradigm.

Derazantinib Continues to Elicit Encouraging Responses in FGFR2 Gene Fusion–Positive Intrahepatic Cholangiocarcinoma

June 2nd 2021

Derazantinib continued to induce encouraging responses in patients with FGFR2 gene fusion–positive intrahepatic cholangiocarcinoma, according to updated data from cohort 1 of the phase 2 FIDES-01 trial.

Dr. Hammers on the Potential Utility of HIF-2α Inhibitors in RCC

June 2nd 2021

Hans Hammers, MD, PhD, discusses the potential utility of HIF-2α inhibitors in renal cell carcinoma.

Innovation Fuels Breakthroughs for Rare Cancers

June 2nd 2021

Innovative strategies are vital for patients diagnosed with rare cancers, who are frequently at a disadvantage compared with those who have more common malignancies, experts say.

Dr. Hutson on Safety Considerations With Cabozantinib in mRCC

May 24th 2021

Thomas Hutson, DO, PharmD, discusses key safety considerations with cabozantinib in patients with metastatic renal cell carcinoma.

Dr. Talwar on the Utility of Immunotherapy in Metastatic Urothelial Carcinoma

May 24th 2021

Vineet Talwar, DM, FRCP, DNB, FICP, FIMSA, MNAMS, discusses the utility of immunotherapy in metastatic urothelial carcinoma.

cfMeDIP-seq Provides Opportunity for Early Cancer Detection, Classification, and Monitoring

May 18th 2021

Cell-free methylated DNA immunoprecipitation-sequencing uses plasma cell-free methylomes to detect and classify several types of cancer early on, and provides the opportunity to monitor tumors for response to treatment in noninvasive way.

Dr. Rini on the Results of an Exploratory Analysis of the IMmotion151 Trial in mRCC

May 17th 2021

Brian I. Rini, MD, discusses the results of an exploratory analysis of the phase 3 IMmotion151 trial in metastatic renal cell carcinoma.

Grivas and Wright Weigh In on the Benefits of Multidisciplinary Care in Bladder Cancer

May 17th 2021

Drs Grivas and Wright discussed the goals of the Seattle Cancer Care Alliance Bladder Cancer Multidisciplinary Clinic, data that support the use of a multidisciplinary approach in bladder cancer, and the lingering effects of the COVID-19 pandemic on collaboration across health care specialties.

Dr. Sonpavde on Anticipated Data in Bladder Cancer

May 12th 2021

Guru P. Sonpavde, MD, discusses anticipated data in bladder cancer.

Dr. Hammers on the Importance of Assessing Quality of Life in RCC

May 12th 2021

Hans Hammers, MD, PhD, discusses the importance of assessing quality of life in renal cell carcinoma.

Tivozanib Boosts RCC Treatment Portfolio

May 10th 2021

Daniel J. George, MD, discussed how tivozanib differs from other TKIs and its potential to fill an unmet need in the treatment of patients with renal cell carcinoma.

FDA Grants Priority Review to Pembrolizumab/Lenvatinib for Advanced RCC and Endometrial Carcinoma

May 6th 2021

The FDA has granted priority review to applications that are seeking 2 approvals of pembrolizumab in combination with lenvatinib in advanced renal cell carcinoma and advanced endometrial carcinoma.

Tivozanib Approval Adds to the Armamentarium in Relapsed/Refractory Advanced RCC

May 2nd 2021

Brian I. Rini, MD, discusses the unique characteristics of tivozanib, how the FDA approval of the VEGF inhibitor is poised to further the advanced RCC paradigm, and the potential future utility of the agent.